LINK:

OBJECTIVES: Upon completion of this activity, the participant should be able to:

1. Identify the mechanism of action of PCSK9 Inhibitors
2. Differentiate the major trials of the PCSK9's including ODYSSEY and FOURIER
3. Comprehend current Guidelines for lipid lowering therapy
4. Discuss future directions of PCSK9's

FACULTY DISCLOSURE: Patrick Strickland, MD has no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE:  Michael Sills, MD, and Art Signo, RN have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


For information, please contact Stacey Bishop @Stacey.Bishop@BSWHealth.org